Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Feras Khalil

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Biomedicine & Biotechnology|July 1, 2011
Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug developmentFeras Khalil, Stephanie Läer
The AAPS Journal|January 9, 2014
Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drugFeras Khalil, Stephanie Läer
European Journal of Drug Metabolism and Pharmacokinetics|June 18, 2016
Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling ApproachMuhammad Fawad Rasool, Feras Khalil, Stephanie Läer
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 13, 2016
Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic ApproachMuhammad Fawad Rasool, Feras Khalil, Stephanie Läer
Clinical Pharmacokinetics|March 17, 2015
A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flowsMuhammad Fawad Rasool, Feras Khalil, Stephanie Läer
Frontiers in Pharmacology|March 20, 2025
Novel selective glucocorticoid receptor modulator GRM-01 demonstrates dissociation of anti-inflammatory effects from adverse effects on glucose and bone metabolismFlorian Jakob, Stephanie Hennen, Michael Gautrois, et al.
Journal of Pain Research|February 5, 2021
Outcomes of the Pediatric Development Plan of TapentadolMariëlle Eerdekens, Tatjana Radic, Melanie Sohns, et al.
Journal of Pain Research|December 2, 2020
Population Pharmacokinetics of Tapentadol in Children from Birth to <18 Years OldFeras Khalil, Siak Leng Choi, Estelle Watson, et al.
Journal of Pain Research|October 7, 2022
Multiple Dose Pharmacokinetics of Tapentadol Oral Solution for the Treatment of Moderate to Severe Acute Pain in Children Aged 2 to <7 YearsRenata Jończyk, Christoph Beuter, Beata Bulawa, et al.
Clinical Pharmacology in Drug Development|August 15, 2019
Relative Bioavailability of Enalapril Administered as Orodispersible Minitablets in Healthy AdultsAnne Van Hecken, Björn B Burckhardt, Feras Khalil, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Biomedicine & Biotechnology|July 1, 2011
Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug developmentFeras Khalil, Stephanie Läer
The AAPS Journal|January 9, 2014
Physiologically based pharmacokinetic models in the prediction of oral drug exposure over the entire pediatric age range-sotalol as a model drugFeras Khalil, Stephanie Läer
European Journal of Drug Metabolism and Pharmacokinetics|June 18, 2016
Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling ApproachMuhammad Fawad Rasool, Feras Khalil, Stephanie Läer
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 13, 2016
Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic ApproachMuhammad Fawad Rasool, Feras Khalil, Stephanie Läer
Clinical Pharmacokinetics|March 17, 2015
A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flowsMuhammad Fawad Rasool, Feras Khalil, Stephanie Läer
Frontiers in Pharmacology|March 20, 2025
Novel selective glucocorticoid receptor modulator GRM-01 demonstrates dissociation of anti-inflammatory effects from adverse effects on glucose and bone metabolismFlorian Jakob, Stephanie Hennen, Michael Gautrois, et al.
Journal of Pain Research|February 5, 2021
Outcomes of the Pediatric Development Plan of TapentadolMariëlle Eerdekens, Tatjana Radic, Melanie Sohns, et al.
Journal of Pain Research|December 2, 2020
Population Pharmacokinetics of Tapentadol in Children from Birth to <18 Years OldFeras Khalil, Siak Leng Choi, Estelle Watson, et al.
Journal of Pain Research|October 7, 2022
Multiple Dose Pharmacokinetics of Tapentadol Oral Solution for the Treatment of Moderate to Severe Acute Pain in Children Aged 2 to <7 YearsRenata Jończyk, Christoph Beuter, Beata Bulawa, et al.
Clinical Pharmacology in Drug Development|August 15, 2019
Relative Bioavailability of Enalapril Administered as Orodispersible Minitablets in Healthy AdultsAnne Van Hecken, Björn B Burckhardt, Feras Khalil, et al.
Pageof 2